Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784749 | 0.86 | PARP1 (0.51) | MAPTKDM4ESMN1; SMN2LMNAPARP1 | |
| SCHEMBL1046464 | 0.77 | CDK4 (0.44) | KDM4ESMN1; SMN2PARP1SIRT2CA12 | |
| SCHEMBL30846772 | 0.75 | PARP1 (0.42) | KDM4ELMNAPARP1SIRT2CA12 | |
| SCHEMBL1416592 | 0.72 | MAPT (0.50) | MAPTKDM4ESMN1; SMN2LMNAPARP1 | |
| SCHEMBL26675637 | 0.72 | PARP1 (0.51) | MAPTKDM4ESMN1; SMN2LMNAPARP1 | |
| SCHEMBL4464552 | 0.72 | MAPT (0.50) | MAPTKDM4ESMN1; SMN2LMNAPARP1 | |
| SCHEMBL17926392 | 0.71 | PDE3B (0.44) | KDM4EKMT2A | |
| SCHEMBL13166527 | 0.71 | MAPT (0.48) | MAPTKDM4ESMN1; SMN2LMNAPARP1 | |
| SCHEMBL3344660 | 0.71 | PARP1 (0.39) | KDM4EPARP1DAOATAD2CDK4 | |
| SCHEMBL20772502 | 0.71 | ACVR1 (0.59) | ERN1CA12CA9AURKAACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349999-B1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIV SAARLAND (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8912186-B2 | Allosteric protein kinase modulators | UNIVERSITAET DES SAARLANDES (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177510-A1 | Allosteric protein kinase modulators | Universität des Saarlandes (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S. | 2004-02-12 | — | — | US | disclosed |
| US-6624186-B2 | Modulators of SKCa, IKCa and BKCa channels. | NEUROSEARCH A/S (DK) | 2003-09-23 | — | — | US | disclosed |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-05-09 | — | — | US | disclosed |
| EP-1144387-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000034248-A1 | NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029937-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | MAPT 2470/4885KDM4E 615/4885SMN1; SMN2 3160/4885 |
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | MAPT 964/4885KDM4E 1893/4885SMN1; SMN2 4389/4885 |
| US-20020055526-A1 | Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents | KCNJ2, KCNJ1, KCNJ11 | MAPT 2470/4885KDM4E 615/4885SMN1; SMN2 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.